Patient-reported outcomes (PROs) for tivozanib (TIVO) + nivolumab (NIVO) vs TIVO monotherapy in patients with renal cell carcinoma (RCC) following an immune checkpoint inhibitor (ICI): Results of the phase 3 TiNivo-2 study.
Katy Beckermann(Vanderbilt University Medical Center), Bradley A. McGregor(Harvard University), Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal), Alex Chehrazi‐Raffle(City of Hope), Toni K. Choueiri(Harvard University), Pedro C. Barata(University Hospitals Seidman Cancer Center), Claudia Lebedinsky(European Institute of Oncology), Benjamin Garmezy(Sarah Cannon), Rana R. McKay(University of California San Diego), Sheik Emambux(Centre Hospitalier Universitaire de Poitiers), Edgar Braendle(AVEO Oncology (United States)), Roberto Iacovelli(Agostino Gemelli University Polyclinic), Laurence Albigès(Université Paris-Saclay), Bo Jin(Jilin University), Hans J. Hammers(Southwestern Medical Center), Daniel Yick Chin Heng(University of Calgary), Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Philippe Barthélémy(Centre National de la Recherche Scientifique)
Cited by 0
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
|New England Journal of Medicine|2018|4.6k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k